KAZAN, Russian Federation,
April 6 /PRNewswire-FirstCall/ -
Neuro-Biotech Corp. (Pink Sheets: MRES) (OTCQB) Mr. Rustern Yusupov
Vice-President Neuro-Biotech Corp. Is pleased to announce that
after discussions between Neuro-Biotech Corp and Credo-TM the
company approved the new direction of the company. Mr. Yusupov said
that the both Company Boards have approved the immediate
implementation of the business plan that has been in development
for the past few months. And following the meeting with Auric
Pharma Science, the new board has decided not to pursue any longer
the unsolicited offer that was made by Auric, since after long
discussions both companies were not able to agree on a common
direction for Neuro-Biotech.
Mr. Yusupov also said that a third party has been
identified to produce the test kit, also two laboratories
that met Neuro-Biotech's tests standards that have the
qualified technical personnel. Neuro-Biotech will be providing the
required laboratory technician to train the personnel in
implementing Neuro-biotech's testing procedures.
Also Mr. Yusupov added that on March
28th, during the Quebec/Russia
Innovations Forum which was held in Montreal Technoparc
Neuro-Biotech's representative made a presentation to the deputy
minister of Ministry of Economical Development of Russian Federation, since Bio-technology field
is a major interest for the Russian government and Neuro-Biotech's
has developed a very unique and innovative products which is ready
to market. This makes Neuro-Biotech to qualify for major private
and Russian government funding and grants.
"Every one at Neuro-Biotech is anxious to start producing our
products Now that all elements are in place and our product is in
great demand as it assists the medical field to provide easy and
fast diagnostic treatment to their patient, this will also help
private and public institutions to save millions of dollars in
unnecessary expenses." Stated Mr. Yusupov.
Forward Looking Statements
This release contains statements that are made pursuant to the
Safe Harbor Provisions of the Private Securities Litigation Act of
1995. Certain statements in this press release may contain words
such as "anticipates," "believes," "could," "expects," "intends,"
"may," "projects," "targets" and other similar language that is
considered forward-looking statements. These forward-looking
statements are subject to certain risks and uncertainties and
persons reading this release are cautioned that such statements are
only predictions, and that the Company's actual future results or
performance may be materially different. The Company disclaims any
intention or obligation to update or revise forward-looking
information, whether as a result of new information, future events,
or otherwise, could cause the company's actual results to differ
materially from those indicated in any forward-looking
statements.
SOURCE Neuro-Biotech Corp.